Tart Cherry (Prunus cerasus)

Tart cherry (Prunus cerasus) contains high concentrations of anthocyanins, particularly cyanidin-3-glucosylrutinoside and cyanidin-3-rutinoside, which inhibit cyclooxygenase (COX-1 and COX-2) enzymes involved in prostaglandin synthesis. These polyphenolic pigments also demonstrate free radical scavenging capacity in vitro, though robust human clinical evidence remains limited across most proposed health applications.

Origin & History

Tart cherry (Prunus cerasus) is a deciduous tree native to Eurasia, widely cultivated in regions like Michigan and Europe for its sour fruit. The fruit is harvested fresh or processed into extracts, juices, or powders using solvent-based extraction techniques to isolate anthocyanins and other polyphenolic compounds.

Historical & Cultural Context

The research dossier contains no information about traditional or historical medicinal use of tart cherry in any traditional medicine system.

Health Benefits

• Antioxidant activity demonstrated through ABTS radical scavenging assays (in vitro evidence only)
• Anti-inflammatory effects shown in processed products (in vitro studies, no human trials available)
• No clinical evidence for sleep improvement (no human studies found in research)
• No clinical evidence for gout management (no human trials provided)
• No clinical evidence for exercise recovery (no human data available)

How It Works

Tart cherry's primary bioactives, cyanidin-3-glucosylrutinoside and cyanidin-3-rutinoside, competitively inhibit cyclooxygenase-1 and cyclooxygenase-2 enzymes, reducing prostaglandin E2 synthesis and downstream inflammatory signaling. These anthocyanins also scavenge superoxide and hydroxyl radicals as measured by ABTS and ORAC assays in vitro, and may upregulate endogenous antioxidant enzymes including superoxide dismutase. Additionally, tart cherry contains small amounts of melatonin (approximately 0.01–0.2 mcg per gram), which binds MT1 and MT2 receptors in the suprachiasmatic nucleus, though the physiological relevance of these quantities in supplement doses remains unestablished in human trials.

Scientific Research

The research dossier contains no human clinical trials, RCTs, or meta-analyses with PubMed PMIDs. Available data focus solely on chemical composition analysis and in vitro antioxidant capacity measurements rather than human health outcomes.

Clinical Summary

In vitro studies using ABTS radical scavenging assays consistently demonstrate antioxidant activity from tart cherry anthocyanins, but these findings have not been reliably translated into controlled human trials with clinically meaningful endpoints. Anti-inflammatory effects observed in cell-based models using processed tart cherry products have not yet been confirmed in randomized controlled trials with adequate sample sizes. Claims regarding sleep improvement are unsupported by human study data, as no peer-reviewed clinical trials meeting methodological standards have been identified in the published literature. Overall, the current evidence base for tart cherry supplements is primarily preclinical, and consumers should interpret benefit claims with caution pending adequately powered human studies.

Nutritional Profile

Tart cherries (Prunus cerasus) provide approximately 50-60 kcal per 100g fresh weight. Macronutrients: carbohydrates ~12-14g/100g (predominantly fructose and glucose, roughly 4-5g each), dietary fiber ~1.6-2.0g/100g (mix of soluble pectin and insoluble cellulose), protein ~1.0g/100g, fat ~0.3g/100g. Key micronutrients: potassium ~170-220mg/100g (most abundant mineral), vitamin C ~10-15mg/100g (moderate bioavailability, heat-sensitive), vitamin A (as beta-carotene) ~640-1000 IU/100g, small amounts of vitamin K (~2.1mcg/100g), magnesium ~9-11mg/100g, phosphorus ~15-20mg/100g, calcium ~16mg/100g, iron ~0.3-0.4mg/100g (non-heme, relatively low bioavailability without co-ingestion of vitamin C). Bioactive compounds: anthocyanins (primary bioactives) at 40-80mg/100g fresh weight, predominantly cyanidin-3-glucosylrutinoside and cyanidin-3-rutinoside, with concentrations significantly higher in Montmorency variety (~80-120mg/100g); melatonin at notably low concentrations of 0.01-0.13mcg/g (fresh), insufficient on its own to pharmacologically impact sleep but may contribute synergistically; quercetin ~10-25mg/100g; chlorogenic acid ~50-100mg/100g; ellagic acid in minor quantities. Tryptophan present at ~8-9mg/100g (low absolute quantity). Anthocyanin bioavailability from whole fruit is estimated at 5-10% absorption, improved with concurrent dietary fat; processing into juice concentrates anthocyanins but may reduce vitamin C by 30-50%. Dried/frozen forms retain most polyphenols but lose some heat-labile vitamins.

Preparation & Dosage

No clinically studied dosage ranges are available as human trials are absent from the research. No standardization details for anthocyanin content or recommended forms (extract, powder, juice) have been established through clinical research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, quercetin, turmeric, green tea extract, resveratrol

Safety & Interactions

Tart cherry is generally recognized as safe when consumed in food quantities, and concentrated supplements at typical doses of 480–960 mg standardized extract are well tolerated in short-term use, with no serious adverse events reported in available in vitro or limited observational data. Due to its anthocyanin content and potential COX-inhibiting activity, theoretical interactions with anticoagulant medications such as warfarin and antiplatelet drugs like aspirin or clopidogrel cannot be excluded, and caution is warranted. Tart cherry juice is naturally high in sorbitol, which may cause gastrointestinal discomfort, bloating, or diarrhea at high intakes, particularly in individuals with irritable bowel syndrome. Pregnancy and lactation safety has not been formally studied in clinical settings, so supplemental doses beyond normal dietary intake should be avoided without medical supervision.